Form 4: Enanta Pharmaceuticals Chief Scientific Officer Reports Stock Transactions

Or Yat Sun, Chief Scientific Officer of Enanta Pharmaceuticals, reports acquisition of shares through performance share units and subsequent disposal to cover withholding taxes.

Summary

• On February 12, 2025, Or Yat Sun, the Chief Scientific Officer of Enanta Pharmaceuticals, acquired 9,750 shares of common stock due to the vesting of performance share units (PSUs).
• These PSUs vested as a result of meeting two-year research and development milestones in the 2023-2024 period, as determined by Enanta's Compensation Committee.
• On the same day, 4,324 shares were automatically forfeited to cover withholding taxes related to the PSU settlement at a price of $5.59.
• Following these transactions, Or Yat Sun directly owns 374,535 shares of Enanta Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The vesting of PSUs is a positive sign of achieving milestones, but the subsequent disposal for taxes is a standard procedure and doesn't necessarily indicate a negative outlook.

Positives

• The vesting of performance share units indicates that the company has achieved certain research and development milestones.

Negatives

• The disposal of shares to cover withholding taxes reduces the executive's net shareholding.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's view of the company's prospects.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign of the company achieving its research and development goals.
• Employees may be motivated by the achievement of milestones that trigger PSU vesting.

Key Dates